Literature DB >> 35094405

Automatic segmentation of magnetic resonance images for high-dose-rate cervical cancer brachytherapy using deep learning.

S A Yoganathan1, Siji Nojin Paul1, Satheesh Paloor1, Tarraf Torfeh1, Suparna Halsnad Chandramouli1, Rabih Hammoud1, Noora Al-Hammadi1.   

Abstract

PURPOSE: Magnetic resonance (MR) imaging is the gold standard in image-guided brachytherapy (IGBT) due to its superior soft-tissue contrast for target and organs-at-risk (OARs) delineation. Accurate and fast segmentation of MR images are very important for high-quality IGBT treatment planning. The purpose of this work is to implement and evaluate deep learning (DL) models for the automatic segmentation of targets and OARs in MR image-based high-dose-rate (HDR) brachytherapy for cervical cancer.
METHODS: A 2D DL model using residual neural network architecture (ResNet50) was developed to contour the targets (gross tumor volume (GTV), high-risk clinical target volume (HR CTV), and intermediate-risk clinical target volume (IR CTV)) and OARs (bladder, rectum, sigmoid, and small intestine) automatically on axial MR slices of HDR brachytherapy patients. Furthermore, two additional 2D DL models using sagittal and coronal images were also developed. A 2.5D model was generated by combining the outputs from axial, sagittal, and coronal DL models. Similarly, a 2D and 2.5D DL models were also generated for the inception residual neural network (InceptionResNetv2 (InRN)) architecture. The geometric (Dice similarity coefficient (DSCs) and 95th percentile of Hausdorff distance (HD)) and dosimetric accuracy of 2D (axial only) and 2.5D (axial + sagittal + coronal) DL model generated contours were calculated and compared.
RESULTS: The mean (range) DSCs of ResNet50 across all contours were 0.674 (0.05-0.96) and 0.715 (0.26-0.96) for the 2D and 2.5D models, respectively. For InRN, these were 0.676 (0.11-0.96) and 0.723 (0.35-0.97) for the 2D and 2.5D models, respectively. The mean HD of ResNet50 across all contours was 15.6 mm (1.8-69 mm) and 12.1 mm (1.7-44 mm) for the 2D and 2.5D models, respectively. The similar results for InRN were 15.4 mm (2-68 mm) and 10.3 mm (2.7-39 mm) for the 2D and 2.5D models, respectively. The dosimetric parameters (D90) of GTV and HR CTV for manually contoured plans matched better with the 2.5D model (p > 0.6) and the results from the 2D model were slightly lower (p < 0.08). On the other hand, the IR CTV doses (D90) for all of the models were slightly lower (2D: -1.3 to -1.5 Gy and 2.5D: -0.5 to -0.6 Gy) and the differences were statistically significant for the 2D model (2D: p < 0.000002 and 2.5D: p > 0.06). In case of OARs, the 2.5D model segmentations resulted in closer dosimetry than 2D models (2D: p = 0.07-0.91 and 2.5D: p = 0.16-1.0).
CONCLUSIONS: The 2.5D DL models outperformed their respective 2D models for the automatic contouring of targets and OARs in MR image-based HDR brachytherapy for cervical cancer. The InceptionResNetv2 model performed slightly better than ResNet50.
© 2022 American Association of Physicists in Medicine.

Entities:  

Keywords:  MRI; automatic; brachytherapy; deep learning; segmentation

Mesh:

Year:  2022        PMID: 35094405     DOI: 10.1002/mp.15506

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  2 in total

Review 1.  Machine learning in neuro-oncology: toward novel development fields.

Authors:  Vincenzo Di Nunno; Mario Fordellone; Giuseppe Minniti; Sofia Asioli; Alfredo Conti; Diego Mazzatenta; Damiano Balestrini; Paolo Chiodini; Raffaele Agati; Caterina Tonon; Alicia Tosoni; Lidia Gatto; Stefania Bartolini; Raffaele Lodi; Enrico Franceschi
Journal:  J Neurooncol       Date:  2022-06-28       Impact factor: 4.506

2.  The clinical evaluation of atlas-based auto-segmentation for automatic contouring during cervical cancer radiotherapy.

Authors:  Yi Li; Wenjing Wu; Yuchen Sun; Dequan Yu; Yuemei Zhang; Long Wang; Yao Wang; Xiaozhi Zhang; Yongkai Lu
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.